- Home
- ODC vs CELC Comparison
ODC vs CELC Comparison
Compare ODC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODC
- CELC
- Stock Information
- Founded
- ODC 1941
- CELC 2011
- Country
- ODC United States
- CELC United States
- Employees
- ODC N/A
- CELC N/A
- Industry
- ODC Miscellaneous manufacturing industries
- CELC Medical Specialities
- Sector
- ODC Consumer Discretionary
- CELC Health Care
- Exchange
- ODC Nasdaq
- CELC Nasdaq
- Market Cap
- ODC 316.2M
- CELC 327.3M
- IPO Year
- ODC N/A
- CELC 2017
- Fundamental
- Price
- ODC $41.73
- CELC $10.65
- Analyst Decision
- ODC
- CELC Strong Buy
- Analyst Count
- ODC 0
- CELC 6
- Target Price
- ODC N/A
- CELC $30.17
- AVG Volume (30 Days)
- ODC 34.8K
- CELC 363.8K
- Earning Date
- ODC 06-05-2025
- CELC 05-14-2025
- Dividend Yield
- ODC 1.50%
- CELC N/A
- EPS Growth
- ODC 18.90
- CELC N/A
- EPS
- ODC 3.13
- CELC N/A
- Revenue
- ODC $465,340,000.00
- CELC N/A
- Revenue This Year
- ODC N/A
- CELC N/A
- Revenue Next Year
- ODC N/A
- CELC N/A
- P/E Ratio
- ODC $13.86
- CELC N/A
- Revenue Growth
- ODC 8.24
- CELC N/A
- 52 Week Low
- ODC $29.48
- CELC $7.58
- 52 Week High
- ODC $49.72
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- ODC 37.61
- CELC 58.24
- Support Level
- ODC $41.48
- CELC $9.50
- Resistance Level
- ODC $44.05
- CELC $10.48
- Average True Range (ATR)
- ODC 1.40
- CELC 0.90
- MACD
- ODC -0.26
- CELC 0.23
- Stochastic Oscillator
- ODC 4.94
- CELC 98.40
About ODC Oil-Dri Corporation Of America
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups namely Retail and Wholesale Products Group and Business to Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.